These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 15006012)

  • 21. Drug costs: research and development costs: the great illusion.
    Prescrire Int; 2004 Feb; 13(69):32-6. PubMed ID: 15055226
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The economics of drug discovery and the ultimate valuation of pharmacotherapies in the marketplace.
    Sollano JA; Kirsch JM; Bala MV; Chambers MG; Harpole LH
    Clin Pharmacol Ther; 2008 Aug; 84(2):263-6. PubMed ID: 18547999
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force report--Part I.
    Hay JW; Smeeding J; Carroll NV; Drummond M; Garrison LP; Mansley EC; Mullins CD; Mycka JM; Seal B; Shi L
    Value Health; 2010; 13(1):3-7. PubMed ID: 19874571
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Opinions regarding the Academy of Managed Care Pharmacy dossier submission guidelines: results of a small survey of managed care organizations and pharmaceutical manufacturers.
    Nichol MB; Knight TK; Epstein J; Honda DH; Tretiak R
    J Manag Care Pharm; 2007 May; 13(4):360-71. PubMed ID: 17506602
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Pharmacoeconomic analyses--chance or 4th hurdle for innovative drugs].
    Krammer H
    Wien Med Wochenschr; 2006 Dec; 156(23-24):606-11. PubMed ID: 17211764
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Do drug formulary policies reflect evidence of value?
    Neumann PJ; Lin PJ; Greenberg D; Berger M; Teutsch S; Mansley E; Weinstein MC; Rosen AB
    Am J Manag Care; 2006 Jan; 12(1):30-6. PubMed ID: 16402886
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A role for two-stage pharmacoeconomic appraisal? Is there a role for interim approval of a drug for reimbursement based on modelling studies with subsequent full approval using phase III data?
    Hill S; Freemantle N
    Pharmacoeconomics; 2003; 21(11):761-7. PubMed ID: 12859218
    [TBL] [Abstract][Full Text] [Related]  

  • 28. How to improve pharmacoeconomic data generalisability between different countries.
    Li SC
    Expert Opin Pharmacother; 2007 Jul; 8(10):1409-13. PubMed ID: 17661723
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New Drug Reimbursement and Pricing Policy in Taiwan.
    Chen GT; Chang SC; Chang CJ
    Value Health Reg Issues; 2018 May; 15():127-132. PubMed ID: 29704659
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimal drug pricing, limited use conditions and stratified net benefits for Markov models of disease progression.
    Zaric GS
    Health Econ; 2008 Nov; 17(11):1277-94. PubMed ID: 18186544
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A tale of two (or more) cities: geographic transferability of pharmacoeconomic data.
    O'Brien BJ
    Am J Manag Care; 1997 May; 3 Suppl():S33-9. PubMed ID: 10180339
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of generic competition on the price of brand-name drugs.
    Lexchin J
    Health Policy; 2004 Apr; 68(1):47-54. PubMed ID: 15033552
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness guidelines. The experience of Australian manufacturers.
    Gorham P
    Pharmacoeconomics; 1995 Nov; 8(5):369-73. PubMed ID: 10160071
    [No Abstract]   [Full Text] [Related]  

  • 34. Use of health-related quality of life information in managed care formulary decision-making.
    Wu WK; Sause RB; Zacker C
    Res Social Adm Pharm; 2005 Dec; 1(4):579-98. PubMed ID: 17138497
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Criteria for the economic evaluation of lipid studies in health systems.
    Langley PC
    Value Health; 1998 Nov; 1(4):208-11. PubMed ID: 16674540
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Medicine reimbursement recommendations in Canada, Australia, and Scotland.
    Lexchin J; Mintzes B
    Am J Manag Care; 2008 Sep; 14(9):581-8. PubMed ID: 18778173
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Economic advantage of pharmacogenomics - clinical trials with genetic information.
    Ohashi W; Mizushima H; Tanaka H
    Stud Health Technol Inform; 2008; 136():585-90. PubMed ID: 18487794
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug therapy: safety, effectiveness, and economics.
    Brandys J
    Przegl Lek; 2001; 58(4):226-8. PubMed ID: 11450340
    [TBL] [Abstract][Full Text] [Related]  

  • 39. AMCP Format dossier requests: manufacturer response and formulary implications for one large health plan.
    Spooner JJ; Gandhi PK; Connelly SB
    J Manag Care Pharm; 2007; 13(1):37-43. PubMed ID: 17269835
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quality of clinical and economic evidence in dossier formulary submissions.
    Colmenero F; Sullivan SD; Palmer JA; Brauer CA; Bungay K; Watkins J; Neumann PJ
    Am J Manag Care; 2007 Jul; 13(7):401-7. PubMed ID: 17620035
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.